|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 39.83 USD | +4.13% |
|
+12.86% | +15.75% |
Sales 2024 by Business Segment
Sales 2024 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
Pharmaceutical Products | |||||||
Rare Neurological Diseases | 160M | 305M | 438M | 582M | 715M | ||
Total Assets | 427M | 433M | 674M | 811M | 999M | ||
Interest Expense | -28.22M | -23.97M | -15.67M | -23.76M | -17.5M | ||
Income Tax Expense | - | 2.83M | -76.78M | 44.54M | 46.31M | ||
CAPEX | -2M | -100M | -40.17M | -312K | -1.15M | ||
EBT | -36.94M | 37.43M | 105M | 173M | 192M | ||
Gross Profit | 132M | 250M | 354M | 461M | 558M | ||
D&A | 10.24M | 18.84M | 23.38M | 24.36M | 24.11M | ||
Operating Income | 16.99M | 87.53M | 120M | 192M | 191M | ||
Net Income | -36.94M | 34.6M | 181M | 129M | 145M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
United States (U.S.) | 160M | 305M | 438M | 582M | 715M | ||
Total Assets | 427M | 433M | 674M | 811M | 999M | ||
Interest Expense | -28.22M | -23.97M | -15.67M | -23.76M | -17.5M | ||
Income Tax Expense | - | 2.83M | -76.78M | 44.54M | 46.31M | ||
D&A | 10.24M | 18.84M | 23.38M | 24.36M | 24.11M | ||
CAPEX | -2M | -100M | -40.17M | -312K | -1.15M | ||
Gross Profit | 132M | 250M | 354M | 461M | 558M | ||
Net Income | -36.94M | 34.6M | 181M | 129M | 145M | ||
EBT | -36.94M | 37.43M | 105M | 173M | 192M | ||
Operating Income | 16.99M | 87.53M | 120M | 192M | 191M |
- Stock Market
- Equities
- HRMY Stock
- Financials Harmony Biosciences Holdings, Inc.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
